Car(ina) – The NanoSurface Cardiac in vitro assay Platform

Enabling High-throughput Compound Screening with Structurally Matured iPSC-derived Cardiomyocytes

At NanoSurface, we believe that cells in the dish should resemble cells in the body. In the drug development process, the utility of iPSC-based assays is dependent on the physiological relevance and predictive power of the tissue model. Using biomimetic bioengineering techniques to enhance cell-based assays, NanoSurface is working to accelerate the adoption of stem cell technologies early during preclinical drug development, helping get safer medicines to market in less time and at lower cost. 


The NanoSurface Car(ina) Platform

leverages organized, structurally matured iPSC-derived cardiomyocytes for highly predictive drug screening.

Platform Overview

NanoSurface-Icons_three cell green with nanotopography

Step 1: iPSC-derived cardiomyocytes are seeded into assay plates with NanoSurface topography.

Verified compatible with CiPA-validated commercial iPSC-derived cardiomyocyte cell lines of high purity.

NanoSurface-Icons_Structurally Mature Cells Green copy.png

Step 2: Cardiac microtissues undergo structural and phenotypic maturation:

Cardiac microtissues undergo structural and phenotypic maturation: tissue alignment and anisotropic cellular development, electrophysiological function, improved sarcomeric development, polarized expression of gap junction proteins (Cx43), and upregulation of protein isoforms (cTnI and β-MyHC).

website-edit-NanoSurface-Icons_EKG data green copy.png

Step 3: Multiplexed endpoint assays.

The NanoSurface Car(ina) platform is natively compatible with any assay that can be run on a standard microplate. Access metabolic, electrophysiological, transcriptomic, optical mapping, calcium handling, contractility, fluorescence, structural, and biomarker data all in one integrated platform. Compatible with leading commercial MEA instruments.

Accurately predicting drug effects using cell-based assays requires the generation of model tissues that closely resemble structural and functional aspects of native tissues. Microenvironmental cues play a central role in the development of cellular structure and function. Creating representative stem-cell derived tissues in the dish that provide predictive responses to pharmacological and pathological challenge requires carefully tuning the cellular microenvironment in vitro.

Your Plates, NanoSurfaced

The Car(ina) platform is compatible with familiar plates you are already using in your assay workflows, including plates for leading MEA and impedance assay systems such as the Axion Maestro, ACEA CardioECR, and Nanion Cardioexcyte 96. 

Key Characteristics

NanoSurface Scientist at Microscope

Structurally Matured, Aligned Cardiac Microtissues

Enhanced Reproducibility

High-throughput Screening

Predictive Drug Responses

MEA-based Electrophysiology

Diverse Endpoints

Structurally Matured, Aligned Cardiac Microtissues

NanoSurface Car(ina) tissues comprise iPSC-derived cells that exhibit mature structural and functional phenotypes. Cardiomyocytes cultured on NanoSurface topography exhibit polarized expression of gap junction proteins such as Cx43, develop anisotropic cell shape, striated sarcomeres, tissue-level alignment, as well as achieve enhanced baseline electrophysiology including faster longitudinal conduction velocity and lower resting membrane potential.

Standard iPSC-CM Culture

Standard iPSC-CM Culture

NanoSurface Car(ina) Platform

NanoSurface Car(ina) Platform


Enhanced reproducibility

Enhanced Reproducibility

Tissue alignment and the development of anisotropic cellular morphology contribute to improvements in well-to-well and experiment-to-experiment reproducibility with decreased variability between cultures.

High-throughput Screening

High-throughput Screening

Car(ina) iPSC-derived cardiac tissues offer improved structural development and enhanced pharmacological utility without compromising high-throughput screening compatibility or ease-of-use. The Car(ina) platform is fully compatible with standard microplate formats and can be directly integrated into existing HTS workflows.

Predictive Drug Responses

Predictive Drug Responses

Validated to provide predictive responses to drugs of known effect in CiPA-style drug screening applications for the detection of acute cardiotoxicity and pro-arrhythmia. The Car(ina) platform is capable of detecting acute drug cardiotoxicity with enhanced predictive power and sensitivity compared to standard iPSC-based cardiotoxicity assays.

High-throughput Electrophysiology

MEA-based Electrophysiology

Structural cues are provided without interfering with electrophysiological signal acquisition during industry-standard MEA and impedance measurements. The Car(ina) platform is fully compatible with high-throughput electrophysiological endpoints.

Diverse endpoints

Diverse Endpoints

Plate-based assays offer uncompromising flexibility in experimental design. The Car(ina) platform is natively compatible with any assay that can be run on a standard microplate. Access metabolic, electrophysiological, transcriptomic, optical mapping, calcium handling, contractility, fluorescence, structural, biomarker, and many more datasets all with one integrated platform.




NanoSurface Scientist

The Car(ina) platform is equipped to improve the physiological relevance of a wide range of applications, such as acute CiPA-style cardiotoxicity screening, chronic cardiotoxicity analysis, structural cardiotoxicity, efficacy screening, drug discovery, and disease modeling.

Improve Physiological Relevance and Translational Impact


NanoSurface Car(ina) Platform Launch Brochure

Download the NanoSurface Car(ina) platform brochure for information about the platform in a convenient PDF format. For additional information, please contact

Learn More About
the NanoSurface Car(ina) Platform

If you are interested in learning more about how the NanoSurface Car(ina) platform can accelerate your research, please contact us to arrange a conversation.